Abstract
Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have